Bayerische Motoren Werke ADR (BMWYY)

Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet medical needs, recently received such recognition as its investigational therapy SGX945 was granted Promising Innovative Medicine (“PIM”) designation by the United Kingdom’s (“UK’s”) Medicines and Healthcare products Regulatory Agency (“MHRA”).

As of March 20, 2026, NVIDIA Corporation (NASDAQ:NVDA) has transcended its origins as a high-end graphics chipmaker to become the foundational architect of the global digital economy. Often referred to by analysts as the "Operating System of AI," NVIDIA’s influence now rivals that of the great industrial giants of the 20th century. The company’s trajectory [...]

Enormous resources are being channeled into studying different ways to support the immune system in its fight against cancer. One emerging approach is the use of oncolytic viruses. This approach seeks to leverage viruses to destroy cancer by attacking and killing its cells.

Tesla investors knew they'd be seeing some new competitors -- but many didn't expect this one.

David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers, including doctors, nurse practitioners and nurses have flocked to the Canadian province in search of employment and have secured jobs.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced a partnership with NeuroRPM to implement an FDA-cleared AI platform in its ongoing Parkinson’s disease study, enabling real-time monitoring of symptoms such as bradykinesia, tremor and dyskinesia through wearable and mobile technology, with the data serving as digital biomarkers to enhance disease tracking, support evaluation of buntanetap over the 36-month trial and provide deeper insights into treatment response and future clinical development.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will host a conference call at 8:00 a.m. ET on March 24, 2026, to review financial results for the fiscal year ended Dec. 31, 2025, and provide updates on progress across its drug development programs and the HOPE Therapeutics clinical network, highlighting milestones aligned with its mission to prevent suicide and advance treatments for depression and PTSD.

Telehealth is evolving from a simple video visit into something far more comprehensive: a connected care model that can move a patient from consultation to prescription, fulfillment and follow-up inside one digital pathway. That shift toward fully integrated platforms is changing expectations across healthcare, and Earth Science Tech’s (OTC: ETST) is building exposure to that trend through a portfolio that includes telemedicine platforms, compounding pharmacies and related healthcare services.

Nutriband (NASDAQ: NTRB) announced that the Costa Rica Ministry of Health has approved its line of kinesiology tapes for import and sale, with exclusive distribution partner Innomedica CCB overseeing and financing the regulatory process. The company plans to ramp up marketing efforts in partnership with Innomedica, targeting both its kinesiology tape products and mosquito repellent patch line following the approval.

Medical progress has transformed the treatment of many common illnesses, yet thousands of rare diseases still lack effective therapies. Companies working at the intersection of biotechnology innovation and rare disease research are increasingly focused on addressing these gaps, including Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing and commercializing therapies and vaccines for rare diseases and unmet medical needs.

NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a letter from the FDA’s Bioequivalence Program stating no bioequivalence deficiencies were identified at this time in its Abbreviated New Drug Application, with a preliminary determination ahead of anticipated approval in Summer 2026. The company highlighted its preservative-free ketamine formulation, which excludes benzethonium chloride, as a potential advancement in safety and stability, while continuing to pursue regulatory pathways for broader therapeutic use.

We, Foshan Tiancai Aluminum Co. Ltd., participated in The 16th Zhengzhou International Automobile Exhibition (ZZIAE) , held from June 26th to June 28th, 2025 . Our booth was located at 2C371 2C365 . During this exhibition, we showcased our newly developed products. We welcome you to visit our booth and explore the innovative solutions we have on display.

Most existing cancer treatments not only attack cancer cells but also adversely impact healthy body cells. The resultant damage to healthy tissues usually triggers side effects that often become severe, necessitating discontinuation of therapy or making quality of life worse. Scientists have been looking for better treatments that only impact malignant cells and leave healthy cells unaffected. A new preclinical study documents one such discovery leveraging the use of a mirror-image molecule.

OXNARD, CA - March 16, 2026 - PRESSADVANTAGE - Prestige Bodyworks, a leading collision repair facility in Oxnard, California, continues to advance industry standards through its comprehensive approach to vehicle...

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined, have the potential to improve outcomes and results for cancer patients.

Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent years. However, not all malignancies respond to these therapies, and those that do often become resistant, or are discontinued due to adverse reactions within the immune system. Now, researchers have shown that gut microbiota are one of the key factors influencing the success of immunotherapy targeting PD-L1 and PD-1 gene expression.

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, announced the acquisition of Ignite Proteomics LLC, a commercial-stage precision oncology company focused on improving therapy selection in cancer care through functional proteomics. Ignite’s Reverse Phase Protein Array platform is designed to measure protein expression and activity directly from tumor samples, providing insight into whether targeted therapies are likely to be effective, information that may not be captured by genomic testing alone. Under the terms of the transaction, Aditxt acquired Ignite through the issuance of 36,000 shares of newly designated Series A-2 Convertible Preferred Stock with an aggregate stated value of $36 million, with Ignite to operate as a subsidiary within Aditxt’s oncology initiatives.

As of March 12, 2026, the global aluminum market is navigating a period of intense volatility and structural shifts, with prices on the London Metal Exchange (LME) surging to nearly four-year highs between $3,269 and $3,544 per tonne. While the industry entered the year with cautious optimism, a

California, led by Democratic governor Gavin Newsom, has decided to break with the federal positions on public health and has resolved to stand by policies backed by science rather than the controversial positions being taken by the federal government through its health secretary R. F. Kennedy Jr.

The global trade landscape was thrown into a state of high-stakes volatility this quarter as President Trump issued a stark ultimatum to America’s closest European allies: enter negotiations for the sale of Greenland or face a devastating "Greenland Surcharge" on all exports to the United States. The proposal, which

Voyager Acquisition (NASDAQ: “VACHU,” “VACH,” “VACHW”) announced that holders of 25,217,315 Class A ordinary shares — representing approximately 99.67% of the shares outstanding — exercised their redemption rights in connection with the company’s planned business combination with VERAXA Biotech AG. Following the redemptions, approximately $885,556 will remain in Voyager’s trust account and 82,685 Class A shares will convert into shares of VERAXA Biotech Holding AG, with the combined company expected to trade on Nasdaq under the ticker “VRXA” upon completion of the transaction.

Earth Science Tech (OTC: ETST), a strategic holding company, operates a portfolio in the pharmaceutical, telemedicine, healthcare and consumer markets. The company strives to build value by acquiring and actively managing businesses and focuses on controlling interests in companies where regulatory compliance, operational oversight, and disciplined scaling can drive growth.

Oragenics (NYSE American: OGEN) announced it is exploring potential acquisitions of additional central nervous system assets focused on brain health and brain recovery indications that align with its proprietary intranasal drug delivery platform and lead candidate ONP-002. The company said the initiative complements its existing AI-enabled drug discovery collaboration with Receptor.AI and is intended to build a diversified CNS pipeline, while ONP-002 continues advancing through Phase IIa clinical trials in Australia targeting concussion and mild traumatic brain injury with plans for U.S. Phase IIb studies following a future IND submission.

Monticello, AR - March 10, 2026 - Strokers Diesel Performance & Repair delivers dealer-level diagnostics and specialist expertise for all vehicle categories throughout Monticello and Southeast Arkansas. The shop is widely recognized for solving complex heavy-duty diesel problems on Cummins, Duramax, and Powerstroke engines, but the same premium equipment and diagnostic precision serve Honda, Toyota, Audi, BMW, Volkswagen, and everyday passenger vehicles.

Date: March 10, 2026 Introduction As of early 2026, Tesla Inc. (NASDAQ: TSLA) stands at a defining crossroads that will determine the trajectory of the automotive and tech industries for the next decade. No longer viewed strictly as a car company by its most ardent supporters—nor dismissed as a mere "meme stock" by its harshest [...]